BURLINGTON, Mass., March 1 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. announced today that the Palomar Lux1540 Fractional(TM) Laser Handpiece will be introduced at the American Academy of Dermatology’s 64th Annual Meeting in San Francisco from March 4th to 6th and will be on hand for investor demonstrations. At that time, Management will be available to discuss Palomar’s full line of products at the San Francisco Moscone Convention Center, booth #3139.
The new Palomar Lux1540 Fractional(TM) Laser Handpiece uses patented fractional technology to create precisely defined zones of elevated temperature within the tissue. By varying treatment parameters, diverse effects can be induced in these zones with minimal damage to the surrounding tissue. The advantage of such a device is its ability to create a pattern of isolated columns of coagulation in the epidermis and dermis, without damage to the tissue surrounding the columns. Location, shape and dimensions of these columns can be accurately tuned to achieve the desired clinical effect. One benefit of fractional technology over conventional bulk-treatment approaches is that it provides an increased safety margin, resulting from the fact that a large volume of tissue remains intact. At the same time, the surface-to-volume ratio of the treated area is maximized, which may result in more effective tissue healing and collagen remodeling. That, in turn, may lead to enhanced smoothing of periorbital wrinkles and overall skin resurfacing. Equally important, it means less discomfort and minimal downtime for the customer.
This handpiece is pending FDA clearance for soft tissue coagulation, and Palomar intends to seek additional clearances for skin resurfacing, wrinkles, pigmented lesions such as lentigines, melasma and dyschromia, and others. The Lux1540 is an attachment for the popular StarLux(R) Pulsed Light and Laser System which offers hair removal, photofacials for pigmented and vascular lesions, acne treatment, leg vein clearance, and many other aesthetic applications. Palomar plans to begin shipments of the Palomar Lux1540 Fractional(TM) Laser Handpiece this summer.
Chief Executive Officer Joseph P. Caruso commented, “We continue to be a market leader in the development of new technology. For over eight years, Palomar has been developing fractional technology to provide an effective, safe, and versatile technique for phototreatment of various skin conditions. We are pleased to present an expansion opportunity for those who wish to capitalize on additional markets while offering flexibility and versatility at a low cost.”
To reserve a time to meet with Palomar management and/or receive product demonstrations, please contact Palomar’s Investor Relations’ department at 781-993-2411 or ir@palomarmedical.com.
About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is uniquely focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has an agreement with The Gillette Company to develop and potentially commercialize a patented home-use, light-based hair removal device for women, an agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne, and was awarded a contract by the Department of the Army to develop a light-based self-treatment device for Pseudofolliculitis Barbae (“PFB”).
For more information on Palomar and its products, visit Palomar’s website at http://www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations’ section of the website.
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including but not limited to statements relating to new markets, development and introduction of new products, and financial projections that involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, and/or other factors, which are detailed from time to time in the Company’s SEC reports, including the report on Form 10-K for the year ended December 31, 2004 and the Company’s quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact: Kayla Castle Investor Relations Manager Palomar Medical Technologies Inc 781-993-2411 ir@palomarmedical.com
Palomar Medical Technologies Inc
CONTACT: Kayla Castle, Investor Relations Manager of Palomar MedicalTechnologies Inc, +1-781-993-2411, ir@palomarmedical.com
Web site: http://www.palomarmedical.com/
Company News On-Call: http://www.prnewswire.com/comp/107555.html /
